How will the final overal survival results of PALOMA-3 affect your practice?

I will generally give a trial of first line endocrine therapy with an AI if endocrine-sensitive disease, and reserve Paloma-3 regimen to second line. Endocrine sensitivity can be inferred clinically by disease course (late relapse, recurrence off adjuvant endocrine therapy, asymptomatic status/or mi...